在间歇性囊炎/膀疼痛综合征中富含血小板血:系统性审查和元分析
Sakineh Hajebrahimi1,2, Fateme Tahmasbi3, Elham Jahantabi2
1Research Center for Evidence-Based Medicine, Iranian EBM Centre: A JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Advanced pharmaceutical bulletin
|December 17, 2025
概括
富血小板血 (PRP) 疗法在治疗间歇性囊炎/膀疼痛综合征 (IC/BPS) 方面表现有前途,显著减少疼痛和尿路症状. 需要进一步的研究来证实它的有效性和了解它的机制.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 再生医学是一种再生医学.
背景情况:
- 间歇性囊炎/膀疼痛综合征 (IC/BPS) 是一种慢性疾病,其特征是膀疼痛和尿急.
- 目前IC/BPS的治疗选择存在局限性,需要新的治疗方法.
研究的目的:
- 系统地审查和评估富血小板血 (PRP) 治疗治疗IC/BPS的安全性和有效性.
主要方法:
- 在多个数据库中进行了全面的文献搜索,截至2023年12月5日.
- 系统性审查包括了13项涉及426名患者的研究.
- 评估的结果包括疼痛评分 (VAS),IC症状 (O'Leary-Sant评分),尿动频率,夜尿和膀容量.
主要成果:
- 与基线相比,PRP治疗显示疼痛得分显著降低 (MD: -1.93,95% CI: -2.28, -1.58).
- 亚组分析证实,在注射PRP后,VAS得分下降.
- 在治疗后的O'Leary-Sant得分和IC症状中观察到显著的改善.
结论:
- PRP疗法为IC/BPS提供了一个潜在的新和有效的治疗选择.
- 需要进行进一步的受控研究,以优化治疗方案,并阐明PRP在IC/BPS中的作用机制.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
221
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
221
Drugs for Treatment of Constipation-Predominant IBS
676
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
676
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436


